tiprankstipranks
Teva Pharmaceutical Industries Limited (IL:TEVA)
TASE:TEVA
Israel Market
TEVA
Teva
RESEARCH TOOLSreports
Want to see IL:TEVA full AI Analyst Report?

Teva (TEVA) Stock News & Sentiment

50 Followers
Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
Premium
Ratings
Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
23d ago
TEVA
Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook
Premium
Ratings
Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook
3M ago
TEVA
Teva Pharmaceutical: Strategic Focus and Financial Stability Drive Buy Rating
Premium
Ratings
Teva Pharmaceutical: Strategic Focus and Financial Stability Drive Buy Rating
8M ago
TEVA
Teva Pharmaceutical’s Favorable Position in IRA Negotiations Drives Buy Rating
Premium
Ratings
Teva Pharmaceutical’s Favorable Position in IRA Negotiations Drives Buy Rating
10M ago
TEVA
Teva Pharmaceutical’s Austedo Poised for Growth: Analyst Recommends Buy Rating
Premium
Ratings
Teva Pharmaceutical’s Austedo Poised for Growth: Analyst Recommends Buy Rating
10M ago
TEVA
Teva Pharmaceutical’s Promising Growth Prospects and Strategic Initiatives Drive Buy Rating
Premium
Ratings
Teva Pharmaceutical’s Promising Growth Prospects and Strategic Initiatives Drive Buy Rating
11M ago
TEVA
Teva Pharmaceutical’s Strategic Edge and Growth Potential: Analyst Recommends Buy Rating
Premium
Ratings
Teva Pharmaceutical’s Strategic Edge and Growth Potential: Analyst Recommends Buy Rating
11M ago
TEVA
More IL:TEVA News >

TEVA News on the Web

Einhorn’s DME takes stakes in StubHub, Paramount, buys more Peloton
TipRanks News
Bearish
Teva price target raised to $40 from $38 at Barclays
TipRanks News
Neutral
Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
TipRanks News
Neutral
Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
TipRanks News
Bullish
Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
TipRanks News
Bullish
Teva price target raised to $45 from $42 at Truist
TipRanks News
Bullish
Morning Movers: NXP Semi, Bloom Energy charged up after results
TipRanks News
Bullish
Notable companies reporting before tomorrow’s open
TipRanks News
Bearish

News Score - Last 7 Days

Very Negative
IL:TEVA
Sector Average
Media Buzz
This Week1 articles
Weekly Average2 articles
News Sentiment
This Week0%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IL:TEVA’s Media Buzz Sentiment?
1 articles about IL:TEVA were published this week. In an average week, 2 articles are published.
    What is IL:TEVA’s weekly average amount of articles?
    In an average week, 2 articles about IL:TEVA are published.
      What is IL:TEVA’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      GOSSGossamer Bio
      RLAYRelay Therapeutics
      ROIVRoivant Sciences
      ILAIsland Pharmaceuticals Ltd
      JUNSJupiter Neurosciences, Inc.
      Showing the stocks with the most bullish news sentiment over the past week